- A-Z Publications
- Journal of Endocrinology, Metabolism and Diabetes in South Africa
- Previous Issues
- Volume 13, Issue 1, 2008
Journal of Endocrinology, Metabolism and Diabetes in South Africa - Volume 13, Issue 1, 2008
Volume 13, Issue 1, 2008
Source: Journal of Endocrinology, Metabolism and Diabetes in South Africa 13, pp 8 –12 (2008)More Less
Until 2002, hormone [replacement] therapy (HT) was first-line therapy for prevention (and treatment) of postmenopausal osteoporosis (PMOP). It was thought that any risks associated with HT were far outweighed by potential long-term benefits (mainly cardiovascular protection). Although there were rumblings from some smaller studies at the turn of the millennium, the Women's Health Initiative (WHI) results, published in 2002, changed the way in which we managed PMOP. In this large randomised study, there was now strong prospective evidence that HT did indeed decrease fracture risk at all major sites. However, the expected benefits in cardiovascular risk were not substantiated. Thereafter, the pendulum swung dramatically away from HT in PMOP; but newer evidence over the last 18 months is causing the pendulum to move back towards a central position. We now review the place of HT in postmenopausal osteoporosis in two parts: firstly, the accumulated evidence for bone protection and, secondly, the current benefits versus risk perspective, as well as up-to-date recommendations for its use.
Source: Journal of Endocrinology, Metabolism and Diabetes in South Africa 13, pp 14 –17 (2008)More Less
Diabetes mellitus is a known independent risk factor for coronary artery disease (CAD) and other macrovascular complications, including stroke and peripheral vascular disease. Cardiovascular disease is a major cause of morbidity and mortality in people with type 2 diabetes. People with type 2 diabetes are disproportionately affected with cardiovascular disease compared with those without diabetes.
Source: Journal of Endocrinology, Metabolism and Diabetes in South Africa 13, pp 18 –19 (2008)More Less
Multiple endocrine neoplasia type 2A (MEN-2A) is an autosomal dominant genetic syndrome consisting of medullary thyroid carcinoma, phaeochromocytoma and hyperparathyroidism. A germline mutation in the RET proto-oncogene which codes for tyrosine kinase receptors expressed in neural-crest derived cells of the thyroid, the parathyroid, adrenal medulla and enteric autonomic plexus results in this syndrome. Genetic testing for mutations in the RET proto-oncogene should now be the standard of care for the diagnosis and screening of families with MEN-2A. This report describes a 34-year-old Congolese man with newly diagnosed MEN-2A.
43rd SEMDSA and 13th NOFSA Congresses and 11th DESSA Workshop : 12 - 15 April 2008, Cape Town : abstractsSource: Journal of Endocrinology, Metabolism and Diabetes in South Africa 13, pp 20 –44 (2008)More Less